Physician profile
Serban I Cocioba
NPI 1821120833
$711.74
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $81.56 · 2021: $197 · 2022: $83.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $200.39 | 2019-2020 | |
| Abbvie INC. | $195.66 | 2021-2022 | |
| Glaxosmithkline, LLC. | $141.85 | 2019-2021 | |
| Lilly USA, LLC | $60.97 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.00 | 2020 | |
| Allergan, INC. | $22.05 | 2019 | |
| Novo Nordisk INC | $20.18 | 2021 | |
| Genentech USA, INC. | $19.96 | 2021 | |
| Pfizer INC. | $18.68 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serban Cocioba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.